Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Glomerular filtration rate estimated by cystatin C among different clinical presentations.Kidney Int. 2006; 69: 399-405
- Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation.Clin Chem. 2000; 46: 1206-1207
- A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate.Nephrol Dial Transplant. 2003; 18: 2024-2031
- Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease.Clin Nephrol. 2008; 70: 10-17
- Cystatin C and mortality risk in the elderly: the health, aging, and body composition study.J Am Soc Nephrol. 2006; 17: 254-261
- Cystatin C and the risk of death and cardiovascular events among elderly persons.N Engl J Med. 2005; 352: 2049-2060
- Assessment of kidney function in patients with cancer.Adv Chronic Kidney Dis. 2018; 25: 49-56
- Thyroid function differently affects serum cystatin C and creatinine concentrations.J Endocrinol Invest. 2005; 28: 346-349
- Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement.Kidney Int. 2004; 65: 1416-1421
- Cystatin C serum concentrations underestimate glomerular filtration rate in renal transplant recipients.Clin Chem. 1999; 45: 1866-1868
- OPTN/SRTR 2012 annual data report: heart.Am J Transplant. 2014; 14: 113-138
- KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.Kidney Int. 2014; 85: 1303-1309
- New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.Am J Transplant. 2004; 4: 583-595
- Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.Kidney Int. 2001; 59: 732-737
- KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.Kidney Int. 2010; 77: 299-311
- Infectious complications after kidney transplantation: current epidemiology and associated risk factors.Clin Transplant. 2006; 20: 401-409
- Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers.Clin Transplant. 2005; 19: 230-235
- Late urinary tract infection after renal transplantation in the United States.Am J Kidney Dis. 2004; 44: 353-362
- Urinary tract infections in solid organ transplantation.Am J Transplant. 2013; 13: 327-336
- Cytomegalovirus in solid organ transplant recipients.Am J Transplant. 2009; 9: S78-S86
- Epstein-Barr virus infection in adult renal transplant recipients.Am J Transplant. 2014; 14: 1619-1629
- Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial.Transplantation. 2005; 80: 1194-1197
- Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.Am J Transplant. 2012; 12: 1157-1167
- Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.Transplantation. 2013; 95: 410-417
- De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure.Am J Transplant. 2009; 9: 2532-2541
- Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation.J Am Soc Nephrol. 2005; 16: 2804-2812
- Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.Am J Transplant. 2015; 15: 2921-2930
- Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.Clin Transpl. 2011; : 359-364
- De novo donor specific antibodies and patient outcomes in renal transplantation.Clin Transpl. 2011; : 351-358
- Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies.Am J Transplant. 2013; 13: 485-492
- The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss.Am J Transplant. 2017; 17: 1574-1584
- Luminex((R)) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion.Transfus Med Hemother. 2013; 40: 182-189
- Positive virtual crossmatch with negative flow crossmatch results in two cases.Transpl Immunol. 2011; 25: 77-81
- Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation.Eur J Immunol. 2015; 45: 2111-2121
- The 'HLA conundrum in bone marrow transplantation': correct interpretation of anti-HLA antibodies in haploidentical donor selection.Bone Marrow Transplant. 2017; 52: 902-904
- Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies.Transplantation. 2009; 87: 813-820
- The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays.Transplantation. 2007; 84: 258-264
- Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays.Transplantation. 2014; 98: 625-631
- HLA antibody specification using single-antigen beads—a technical solution for the prozone effect.Transplantation. 2011; 92: 510-515
- Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution.Hum Immunol. 2009; 70: 496-501
- Assessing antibody strength: comparison of MFI, C1q, and titer information.Am J Transplant. 2015; 15: 2421-2430
- The role of complement in antibody-mediated rejection in kidney transplantation.Nat Rev Nephrol. 2012; 8: 670-678
- Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.Hum Immunol. 2011; 72: 849-858
- Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.J Am Soc Nephrol. 2015; 26: 457-467
- Complement-binding anti-HLA antibodies and kidney-allograft survival.N Engl J Med. 2013; 369: 1215-1226
- Complement-binding anti-HLA antibodies and kidney transplantation.N Engl J Med. 2014; 370: 84
- Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.J Heart Lung Transplant. 2013; 32: 98-105
- Determinants of C1q binding in the single antigen bead assay.Transplantation. 2014; 98: 387-393
- Comparison between total IgG, C1q, and C3d single antigen bead assays in detecting class I complement-binding Anti-HLA antibodies.Transplant Proc. 2017; 49: 2031-2035
- C1q single antigen bead assay only detects high titer/avidity class-I anti HLA antibodies detected by single antigen beads.Hum Immunol. 2014; 75: 73
- Divergent immunoglobulin G subclass activity through selective Fc receptor binding.Science. 2005; 310: 1510-1512
- Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation.Liver Transpl. 2012; 18: 984-992
- Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year.Am J Transplant. 2012; 12: 1504-1510
- Impact of donor-specific antibodies on results of liver transplantation.Curr Opin Organ Transplant. 2013; 18: 279-284
- The role of donor-specific HLA alloantibodies in liver transplantation.Am J Transplant. 2014; 14: 779-787
- Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients.Transplantation. 2014; 97: 494-501
- Donor-specific alloantibody after positive crossmatch kidney transplant with eculizumab: correlation with transplant glomerulopathy and graft failure.Am J Transplant. 2015; 15 ([abstract])
- The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.Transplantation. 2013; 95: 1113-1119
- IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury.J Am Soc Nephrol. 2016; 27: 293-304
- Evaluating the accuracy of functional biomarkers for detecting histological changes in chronic allograft nephropathy.Transpl Int. 2007; 20: 608-615
- Identifying specific causes of kidney allograft loss.Am J Transplant. 2009; 9: 527-535
- Subclinical rejection in tacrolimus-treated renal transplant recipients.Transplantation. 2002; 73: 1965-1968
- Natural history, risk factors, and impact of subclinical rejection in kidney transplantation.Transplantation. 2004; 78: 242-249
- Effect of histological damage on long-term kidney transplant outcome.Transplantation. 2001; 71: 515-523
- Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center.Am J Transplant. 2005; 5: 1354-1360
- Infiltrates in protocol biopsies from renal allografts.Am J Transplant. 2007; 7: 356-365
- Predicting subsequent decline in kidney allograft function from early surveillance biopsies.Am J Transplant. 2005; 5: 2464-2472
- Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury.Am J Transplant. 2018; 18: 180-188
- Utility of protocol kidney biopsies for de novo donor-specific antibodies.Am J Transplant. 2017; 17: 3210-3218
- Protocol transplant biopsies: an underutilized tool in kidney transplantation.Clin J Am Soc Nephrol. 2006; 1: 138-143
- Beneficial effects of treatment of early subclinical rejection: a randomized study.J Am Soc Nephrol. 1998; 9: 2129-2134
- Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study.Am J Transplant. 2007; 7: 2538-2545
- Kidney allograft surveillance biopsy practices across US transplant centers: a UNOS survey.Clin Transplant. 2017; 31
- Safety and adequacy of renal transplant protocol biopsies.Am J Transplant. 2005; 5: 1992-1996
Article info
Publication history
Published online: October 05, 2018
Footnotes
Disclosure Statement: KL2 TR002379 National Center for Advancing Translational Science (NCATS)
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
